As the first installment in the 2026 Johnson&Johnson and Legend CAR T Series, join Dr. Joy Ho and Dr. Marco Davila as they explore the latest advances in in vivo CAR T cell therapy, offering...
by Julian Guetta-Weiss, Chenyu Lin
As CAR T-cell therapy increasingly moves into the outpatient setting, remote digital monitoring technologies are helping clinicians detect toxicities earlier, enhance patient safety, and support...
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP and Mark Hamilton, MD, of The University of Texas MD Anderson Cancer Center discuss immune effector cell-associated...
by Frederick Locke
Our latest committee member spotlight features Frederick L. Locke, MD, chair of the Department of Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center and chair of...
by Molecular Therapy Advances
Scientists believe lentiviral (LV)-based virus-like particles (VLPs) could improve chimeric antigen receptor (CAR) T-cell therapies and enable rapid, scalable production of gene-edited CAR T-cells...
by Blood
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD70 has the potential to improve outcomes in individuals with follicular lymphoma (FL) who have elevated relapse risk.